CRISPR Therapeutics CRSP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.1M-89.1% | $3.51M-90.6% | $38.34M-81.1% | $38.05M-81.2% | $37.68M-86.1% | ||
| $280.9M-8.4% | $284.81M-8.2% | $273.02M-18.2% | $296.28M-13.4% | $306.55M-15.7% | ||
| $71.43M-3.9% | $73.54M+0.8% | $73.27M+2.7% | $73.76M+2.1% | $74.32M+3.6% | ||
| $650.5M+27.0% | $668.08M+32.6% | $612.73M+14.5% | $590.52M+6.0% | $512.08M-10.2% | ||
| -$646.4M-36.3% | -$664.57M-42.4% | -$574.4M— | -$552.47M— | -$474.4M— | ||
| -15,754.2%-14,495pp | -18,933.6%-17,683pp | -1,498.3%— | -1,451.9%— | -1,259.2%— | ||
| $81.23M-12.4% | $86.61M-16.6% | $89.82M-6.4% | $88.65M-3.1% | $92.72M+10.6% | ||
| -$565.17M-48.1% | -$577.97M-59.4% | -$484.58M— | -$463.82M— | -$381.69M— | ||
| $3.36M-15.3% | $3.63M+1.3% | $3.72M+19.2% | $3.98M+49.7% | $3.97M+73.3% | ||
| -$568.53M-47.4% | -$581.6M-58.8% | -$488.3M— | -$467.8M— | -$385.66M— | ||
| -13,856.5%-12,833pp | -16,569.8%-15,588pp | -1,273.7%— | -1,229.4%— | -1,023.6%— | ||
| -$6.20-37.8% | -$6.50-49.4% | -$5.57— | -$5.41— | -$4.50— | ||
| -$627.33M-37.8% | -$645.09M-44.2% | -$555.74M— | -$533.5M— | -$455.24M— | ||
| -15,289.6%-14,081pp | -18,378.7%-17,180pp | -1,449.6%— | -1,402.1%— | -1,208.3%— | ||
| -$646.4M-36.3% | -$664.57M-42.4% | -$574.4M— | -$552.47M— | -$474.4M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does CRISPR Therapeutics's income statement data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.